Droit de la consommation

Published: 10 October 2004

  • PEOPLE

    Xavier Favre-Bulle
    Partner, Head of Arbitration
    B. Stauder

  • Details

    Number of pages
    229 pages

Cette édition spéciale réunit les commentaires de ces textes publiés dans le cadre du Commentaire romand du Code des obligations. Les dispositions sur le droit de révocation en matière de démarchage et d'excursion-vente et sur le contrat de voyage à forfait sont commentées pour la première fois en français. Le commentaire de la nouvelle loi sur le crédit à la consommation, qui vise avant tout à prévenir le surendettement du consommateur preneur d'un crédit à la consommation (vente par acomptes, petit crédit, leasing de biens de consommation, crédit en compte-courant, cartes de crédit et de client avec option de crédit), est même le premier à analyser de façon systématique les dispositions de la nouvelle LCC entrée en vigueur le 1er janvier 2003.

(Extrait du Commentaire romand Code des obligations I, édité par Luc Thévenoz et Franz Werro)

Related publications

SEE ALL

Insights

Insights – 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

Insights – 03.08.2026

The EU AI Act: New prohibitions and transparency take effect and what is yet to come

The EU AI Act: New prohibitions and transparency take effect and what is…

<p class="MsoBodyText">Regulation (EU) 2024/1689 of 13 June 2024 (“<strong>EU</strong> <strong>AI Act</strong>”)&nbsp;general application date of <em>2 August 2026</em> has arrived, but the regulatory landscape looks materially different from the original plan.</p> <p class="MsoBodyText">The amending Regulation (EU) 2026/1744 (“<strong>AI Omnibus</strong>”)&nbsp;has deferred the core high-risk AI obligations to 2027, even 2028, while introducing a new prohibition on non-consensual intimate “deepfake” content and a labelling grace period for legacy generative AI systems. This Legal Insight maps the current compliance landscape for Swiss companies with EU market exposure, with a particular focus on implications for the banking and financial services sector.</p>
SEE ALL
Lenz & Staehelin {PAGENO}/{nbpg}
{PAGENO}/{nbpg}